Impact of Neoadjuvant Chemotherapy With Gemcitabine Plus Nab-paclitaxel on the Treatment for Borderline Resectable Pancreatic Cancer

被引：0
|
作者：
Miyasaka, Y. [1 ,2 ]
Ohtsuka, T. [1 ]
Kimura, R. [1 ]
Mori, Y. [1 ]
Nakata, K. [1 ]
Nakamura, M. [1 ]
机构：
[1] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Oncol, Fukuoka, Japan
[2] Fukuoka Univ, Dept Surg, Chikushi Hosp, Chikushino, Japan
来源：
PANCREAS | 2019年 / 48卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1492 / 1492
页数：1
相关论文
共 50 条
  • [31] Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015)
    Yamada, Daisaku
    Kobayashi, Shogo
    Takahashi, Hidenori
    Iwagami, Yoshifumi
    Akita, Hirofumi
    Asukai, Kei
    Shimizu, Junzo
    Yamada, Terumasa
    Tanemura, Masahiro
    Yokoyama, Shigekazu
    Tsujie, Masanori
    Asaoka, Tadafumi
    Takeda, Yutaka
    Morimoto, Osakuni
    Tomokuni, Akira
    Doki, Yuichiro
    Eguchi, Hidetoshi
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (07) : 4621 - 4633
  • [32] Neoadjuvant gemcitabine and nab-paclitaxel for borderline resectable pancreatic cancers: Intention-to-treat analysis compared with upfront surgery
    Inoue, Yosuke
    Saiura, Akio
    Oba, Atsushi
    Ono, Yoshihiro
    Mise, Yoshihiro
    Ito, Hiromichi
    Sasaki, Takashi
    Ozaka, Masato
    Sasahira, Naoki
    Takahashi, Yu
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2021, 28 (02) : 143 - 155
  • [33] Impact of pathological complete response following neoadjuvant chemotherapy (gemcitabine, nab-paclitaxel, S-1) and radiation for borderline resectable pancreatic cancer: a case report and review of literature
    Mitsuru Kinoshita
    Sota Watanabe
    Gaku Mizojiri
    Akitada Sada
    Hiroki Kai
    Yasunori Masuike
    Yoshinobu Nagasawa
    Kentaro Maruyama
    Kyowon Lee
    Mai Ohata
    Osamu Ishikawa
    Hiroshi Oka
    Surgical Case Reports, 8
  • [34] NEONAX: NEOADJUVANT PLUS ADJUVANT OR ONLY ADJUVANT NAB-PACLITAXEL PLUS GEMCITABINE FOR RESECTABLE PANCREATIC CANCER: A PHASE II STUDY OF THE AIO PANCREATIC CANCER GROUP
    Thomas, Ettrich
    Andreas, Berger
    Rainer, Muche
    Manfred, Lutz
    Nicole, Prasnikar
    Waldemar, Uhl
    Andrea, Tannapfel
    Volker, Heinemann
    Thomas, Seufferlein
    ANNALS OF ONCOLOGY, 2014, 25 : 85 - 85
  • [35] Impact of pathological complete response following neoadjuvant chemotherapy (gemcitabine, nab-paclitaxel, S-1) and radiation for borderline resectable pancreatic cancer: a case report and review of literature
    Kinoshita, Mitsuru
    Watanabe, Sota
    Mizojiri, Gaku
    Sada, Akitada
    Kai, Hiroki
    Masuike, Yasunori
    Nagasawa, Yoshinobu
    Maruyama, Kentaro
    Lee, Kyowon
    Ohata, Mai
    Ishikawa, Osamu
    Oka, Hiroshi
    SURGICAL CASE REPORTS, 2022, 8 (01)
  • [36] Neoadjuvant Nab-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX
    Peterson, Shawn L.
    Husnain, Muhammad
    Pollack, Terri
    Pimentel, Agustin
    Loaiza-Bonilla, Arturo
    Westendorf-Overley, Colleen
    Ratermann, Kelley
    Anthony, Lowell
    Desimone, Philip
    Goel, Gaurav
    Kudrimoti, Mahesh
    Dineen, Sean
    Tzeng, Ching-Wei D.
    Hosein, Peter J.
    ANTICANCER RESEARCH, 2018, 38 (07) : 4035 - 4039
  • [37] Neoadjuvant gemcitabine and nab-paclitaxel followed by concurrent capecitabine/radiation in borderline resectable (BR) pancreatic cancer: A single-institution experience
    Gupta, Niraj K.
    Singh, Kirpal
    Aburajab, Murad
    Mathavan, Vinay
    Al-Satie, Mazen
    Glass, Timothy
    Leagre, Christopher A.
    Rowe, Michael
    Tigges, Thomas
    Liebross, Robert H.
    Davis, Chad
    Tandra, Sweta
    Tumati, Vas
    Tian, Jianmin
    Martinez, Brandon
    Dowell, Joshua
    Schmidt, Kristen Kay
    Flanders, Vincent
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [38] Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection
    Wolfe, Adam R.
    Prabhakar, Dhivya
    Yildiz, Vedat O.
    Cloyd, Jordan M.
    Dillhoff, Mary
    Abushahin, Laith
    Diaz, Dayssy Alexandra
    Miller, Eric D.
    Chen, Wei
    Frankel, Wendy L.
    Noonan, Anne
    Williams, Terence M.
    CANCER MEDICINE, 2020, 9 (13): : 4711 - 4723
  • [39] Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer
    Kunzmann, Volker
    Herrmann, Ken
    Bluemel, Christina
    Kapp, Markus
    Hartlapp, Ingo
    Steger, Ulrich
    CASE REPORTS IN ONCOLOGY, 2014, 7 (03): : 648 - 655
  • [40] Treatment of Borderline Resectable (BR) and Locally Advanced (LA) Pancreatic Cancer in the Era of FOLFIRINOX and Gemcitabine plus Nab-Paclitaxel: A Multi-Institutional Study
    Idrees, K.
    Parikh, A.
    Postlewait, L. M.
    Weber, S.
    Cho, C. S.
    Salem, A. I.
    Martin, R. C.
    Scoggins, C.
    Kim, H. J.
    Carr, J.
    Xia, B.
    Ahmad, S.
    Abbott, D.
    Maithel, S.
    Kooby, D. A.
    Merchant, N.
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 : S23 - S23
12345